<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134327">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01697579</url>
  </required_header>
  <id_info>
    <org_study_id>0517-029</org_study_id>
    <secondary_id>2012-002340-24</secondary_id>
    <nct_id>NCT01697579</nct_id>
  </id_info>
  <brief_title>Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Under 18 Years of Age (MK-0517-029)</brief_title>
  <official_title>A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Emetogenic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the appropriate dosing regimen of fosaprepitant,
      when administered with ondansetron (with or without dexamethasone), for the prevention of
      CINV in children from birth to 17 years of age. Fosaprepitant is a prodrug to aprepitant.
      All participants who complete the randomized Cycle 1 may elect to receive open-label
      fosaprepitant during optional Cycles 2-6.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Aprepitant Area Under the Curve (AUC) from 0 to ∞ hours (0-∞)</measure>
    <time_frame>Up to 25 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Aprepitant Maximum Concentration (Cmax)</measure>
    <time_frame>Up to 25 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Aprepitant Cmax (Tmax)</measure>
    <time_frame>Up to 25 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Aprepitant Terminal Phase Half-Life (t1/2)</measure>
    <time_frame>Up to 25 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Aprepitant Apparent Total Body Clearance (CL/F)</measure>
    <time_frame>Up to 25 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience At Least One Adverse Event</measure>
    <time_frame>Up to 14 days postdose</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Chemotherapy-induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Fosaprepitant 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1: Fosaprepitant 150 mg (or weight-adjusted equivalent for children &lt;12 years of age), administered intravenously (IV) plus ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children &lt;6 months of age), administered IV. Optional Cycles 2-6: Fosaprepitant 150 mg (or weight-adjusted equivalent for children &lt;12 years of age), administered IV plus a 5-hydroxytryptamine 3 (5-HT3) antagonist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fosaprepitant 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1: Fosaprepitant 60 mg (or weight-adjusted equivalent for children &lt;12 years of age), administered IV plus ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children &lt;6 months of age), administered IV. Optional Cycles 2-6: Fosaprepitant 150 mg (or weight-adjusted equivalent for children &lt;12 years of age), administered IV plus a 5-HT3 antagonist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fosaprepitant 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1: Fosaprepitant 20 mg (or weight-adjusted equivalent for children &lt;12 years of age), administered IV plus ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children &lt;6 months of age), administered IV. Optional Cycles 2-6: Fosaprepitant 150 mg (or weight-adjusted equivalent for children &lt;12 years of age), administered IV plus a 5-HT3 antagonist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ondansetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cycle 1: Matching Placebo to fosaprepitant, administered IV plus ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children &lt;6 months of age), administered IV. Optional Cycles 2-6: Fosaprepitant 150 mg (or weight-adjusted equivalent for children &lt;12 years of age), administered IV plus a 5-HT3 antagonist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosaprepitant 150 mg</intervention_name>
    <description>Administered IV as a single dose</description>
    <arm_group_label>Fosaprepitant 150 mg</arm_group_label>
    <other_name>Fosaprepitant dimeglumine</other_name>
    <other_name>MK-0517</other_name>
    <other_name>EMEND® for Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosaprepitant  60 mg</intervention_name>
    <description>Administered IV as a single dose</description>
    <arm_group_label>Fosaprepitant 60 mg</arm_group_label>
    <other_name>Fosaprepitant dimeglumine</other_name>
    <other_name>MK-0517</other_name>
    <other_name>EMEND® for Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosaprepitant  20 mg</intervention_name>
    <description>Administered IV as a single dose</description>
    <arm_group_label>Fosaprepitant 20 mg</arm_group_label>
    <other_name>Fosaprepitant dimeglumine</other_name>
    <other_name>MK-0517</other_name>
    <other_name>EMEND® for Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Fosaprepitant</intervention_name>
    <description>Administered IV as a single dose</description>
    <arm_group_label>Ondansetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Fosaprepitant 150 mg</arm_group_label>
    <arm_group_label>Fosaprepitant 60 mg</arm_group_label>
    <arm_group_label>Fosaprepitant 20 mg</arm_group_label>
    <arm_group_label>Ondansetron</arm_group_label>
    <other_name>Ondansetron hydrochloride</other_name>
    <other_name>Zofran® Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is 0 (at least 37 weeks gestation) to 17 years of age

          -  Scheduled to receive chemotherapeutic agent(s) associated with moderate, high, or
             very high risk of emetogenicity for no more than 5 consecutive days for a documented
             malignancy, or a chemotherapy regimen not previously tolerated due to vomiting

          -  Expected to receive ondansetron as part of antiemetic regimen (Cycle 1); Expected to
             receive a 5-HT3 antagonist as part of antiemetic regimen (Cycles 2-6)

          -  If female and has begun menstruating, must have a negative pregnancy test prior to
             study participation and agree to remain abstinent or use a barrier form of
             contraception

          -  Predicted life expectancy of &gt;=3 months

          -  Pre-existing functioning central venous catheter

          -  Weight &gt;=3rd percentile for age and gender (and &gt;=3.0 kg)

        Exclusion Criteria:

          -  Vomited in the 24 hours prior study drug administration (Cycle 1)

          -  Current user of any illicit drugs (including marijuana) or current evidence of
             alcohol abuse

          -  Scheduled to receive stem cell rescue therapy in conjunction with study related
             course(s) of emetogenic chemotherapy

          -  Received or will receive radiation therapy to the abdomen or pelvis in the week prior
             to study drug administration and/or during the course of the study

          -  Pregnant or breast feeding

          -  Allergic to fosaprepitant, aprepitant, ondansetron, or any other 5-HT3 antagonist

          -  Has a symptomatic central nervous system (CNS) tumor causing nausea and/or vomiting

          -  Has an active infection, congestive heart failure, slow heart rate, or other
             uncontrolled disease other than cancer

          -  Mentally incapacitated or has a significant emotional or psychiatric disorder

          -  Known history of QT prolongation or is taking any medication known to lead to QT
             prolongation

          -  Taking other excluded medications

          -  Participated in any previous study of aprepitant or fosaprepitant, or taken an
             investigational drug within 4 weeks prior to study participation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0122)</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0121)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0002)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0005)</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0004)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme (Argentina) Inc.</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfredo Wilkinson</last_name>
      <phone>54 11 4796 8200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD ýterreich GmbH</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Boegl</last_name>
      <phone>43 126044130</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Brasil</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Germano</last_name>
      <phone>55 11 51897942</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Canada</name>
      <address>
        <city>Kirkland</city>
        <state>Quebec</state>
        <zip>H9H 3L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical Information Centre / Centre de l'information medicale de Merck Canada</last_name>
      <phone>514-428-8600 / 1-800-567-2594</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MDS Colombia SAS</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Carvajal</last_name>
      <phone>57 1219109011090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme OU</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrius Bacevicius</last_name>
      <phone>370 52780243</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme GmbH</name>
      <address>
        <city>Haar</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>German Medical Information Center</last_name>
      <phone>49 800 673 673 673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vianex, S.A. / MSD</name>
      <address>
        <city>Alimos</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Platon Peristaris</last_name>
      <phone>30 2109897322</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Pharma Hungary Kft.</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Martinkova</last_name>
      <phone>36 1 457 8522</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Italia S.r.l.</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Nardini</last_name>
      <phone>39 06 361911</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Korea LTD</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cem Ozesen</last_name>
      <phone>90 212 3361260</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UAB &quot;Merck Sharp &amp; Dohme&quot;</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrius Bacevicius</last_name>
      <phone>370 52780243</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme, Peru S.R.L.</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Espinoza</last_name>
      <phone>(51-1) 411-5100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Lda.</name>
      <address>
        <city>Paco D'arcos</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Maria Nogueira</last_name>
      <phone>351-21-4465890</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Romania SRL</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eran Gefen</last_name>
      <phone>38 (044) 393 74 80</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme IDEA, Inc.</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Koroleva</last_name>
      <phone>7 0959410000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD (Pty) LTD South Africa</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khanyi Mzolo</last_name>
      <phone>27 11 655 3140</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp and Dohme de Espana S.A.</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesar Sanz Rodriguez</last_name>
      <phone>34 913210600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Ilaclari Ltd. Sti</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alev Eren</last_name>
      <phone>90 212 336 12 63</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Ltd.</name>
      <address>
        <city>Hoddesdon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Robinson</last_name>
      <phone>44 1992452396</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Peru</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Chile</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>September 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
